Truist Securities Reiterates Buy Rating, $14 Price Target on Cyclerion Therapeutics (CYCN), Views "Nitrinergic System as Ripe for Therapeutic Intervention"
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $14.00 price target on Cyclerion Therapeutics (NASDAQ: CYCN), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
